Research & Development
Oral therapy combination yields promising results in multiple myeloma study
A new agent that can be taken once daily in pill form showed promising results in a clinical trial when used in combination with a steroid in patients with multiple myeloma who had relapsed and stopped responding to currently available therapies.
September 1, 2023
Pfizer invests $25M to support development of CellCentric’s blood cancer candidate
Evidence of the roles p300 and CBP play in multiple cancers led CellCentric to generate chemical hits against the proteins, ultimately leading to the development of inobrodib.
July 13, 2023
Calculator identifies myeloma patients with favorable prognoses
An open-access calculator tool may help identify patients with more benign multiple forms of multiple myeloma, and help individualize their treatment.
May 5, 2023
Study: Menarini’s CellSearch technology effective in measuring and monitoring CTC levels in multiple myeloma
While biopsy is the conventional method of CTC characterization, Menarini’s minimally invasive Cellsearch platform was found to be an effective tool in the monitoring and management of CTC in patients in the early stages of the disease.
December 15, 2022
Scopio digital platform enables bone marrow aspirate imaging
Bone marrow aspirates are normally conducted manually, using microscopic analysis of cells to diagnose cancers such as leukemia and multiple myeloma.
September 7, 2022
Study recommends screening for adults at risk of multiple myeloma
"We know that in cancers such as breast cancer and lung cancer screening, early detection and early intervention can make a difference in patient survival," senior author Dr. Irene Ghobrial of the Dana-Farber Cancer Institute in Boston said in a statement. "We have shown for the first time that with highly sensitive screening techniques, it may eventually be possible to make a difference in the survival of people at elevated risk for multiple myeloma."
December 10, 2021
Menarini introduces multiple myeloma assay
The new assay captures and enumerates CMMCs from peripheral blood. It has the potential to reduce bone marrow biopsies with a noninvasive method to monitor multiple myeloma evolution and study disease biology.
March 31, 2021
AbbVie gets FDA nod for new use of Venclexta
The approval supports use of Venclexta with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed AML in patients ages 75 or older or those who have comorbidities that preclude the use of intensive induction chemotherapy. AbbVie tested the drug's efficacy using next-generation sequencing in similar trials for multiple myeloma.
October 18, 2020
Sebia teams with Sanofi on myeloma response test
Isatuximab is an anti-CD38 monoclonal antibody. According to the companies, the new Hydrashift 2/4 test will counter potential interference by isatuximab in immunofixation electrophoresis (IFE) tests, which assess complete response to treatment in patients with multiple myeloma. The test kit will be designed for use with Sebia's Hydragel IFE test and will be specifically for isatuximab.
January 6, 2020
AbbVie to deploy Adaptive's clonoSeq test in myeloma trials
Venclexta is currently approved by the U.S. Food and Drug Administration (FDA) for use in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in older patients with newly diagnosed acute myeloid leukemia who can't tolerate intensive chemotherapy. It is being tested for a number of additional indications, including multiple myeloma.
December 8, 2019
Page 1 of 1